Rasmussen syndrome

Short description: Rare neurological inflammatory disease

For the variant of pseudoaneurysm, see Rasmussen aneurysm. For skin condition, see Rasmussen syndrome (dermatology).

Rasmussen syndrome, also known as Rasmussen's encephalitis, is a rare progressive autoimmune neurological disease.[1][2] It is characterized by frequent and severe focal seizures, progressive neurological decline, hemiparesis (weakness on one side of the body), encephalitis, and unilateral cerebral atrophy.[3][4] The disease primarily affects children under the age of 15, though adult cases have been reported.[5] Originally described as a form of chronic focal motor epilepsy by Dr. A. Ya. Kozhevnikov in the 1880s[6] and separately identified as focal seizures due to chronic localized encephalitis in the 1950s by Dr. Theodore Rasmussen.[7] It is now classified to be a cytotoxic T-cell–mediated encephalitis.[8][9][10]

## Contents

* 1 Signs and symptoms
* 2 Pathophysiology
* 3 Diagnosis
* 4 Treatment
* 5 History
* 6 Society
* 7 References
* 8 External links

## Signs and symptoms

The hallmark symptoms are focal seizures, particularly epilepsia partialis continua (EPC), a form of epilepsy characterized by continuous or near-continuous clonic movements in a localized body part.[2][4] These seizures are typically resistant to standard anti-epileptic medications and often mark the early stage of the disease.[5]

This is often seen in the first main stage, sometimes preceded by a 'prodromal stage' of a few months.[1] In the acute stage, which may last between four to eight months, the inflammation is active and symptoms worsen progressively. Children may initially present with subtle behavioral or academic changes before the onset of the drug-resistant focal seizures present.[4][11] Over time as the disease advances, patients develop hemiparesis, hemianopia (vision loss of one side of visual field), and cognitive deficits, involving learning, memory or language.[3][12] In this phase, MRI often reveals hemispheric swelling and beginning signs of atrophy.[13]

The chronic or residual stage occurs after inflammation subsides. While the active immune damage lessens, the neurological deficits persist due to structural brain damage. Patients are often left with long-term epilepsy, paralysis/motor impairment, and cognitive dysfunction, although the severity varies.[5][3] Early diagnosis and treatment may lessen the long term disability in some cases.[12][14]

While Rasmussen's Encephalitis is most commonly diagnosed in children, with an average age of 6 years.[4][15] However, approximately 10% of reported cases begin in adulthood.[16]

## Pathophysiology

Rasmussen's encephalitis is theorized as a T-cell-mediated autoimmune encephalitis, characterized by chronic, progressive inflammation limited to a single hemisphere of the brain.[2][3] Histological analysis of affected brain tissues reveals infiltration of cytotoxic CD8+ T lymphocytes, which target neurons and astrocytes. These immune cells release granzyme B and perforin, a enzyme and protein that kill cells.[3][10] This leads to direct neuronal apoptosis. The presence of activated microglia, identified through HLA-DR and CD68 immunostaining in brain biopsy samples, reflects a broader neuroinflammatory response that contributes to gliosis and progressive neuronal degeneration.[3][1] This immune-mediated damage results in cortical atrophy, which is most pronounced in frontal and insular lobes, along with spreading posteriorly with disease progression.[2][13]

The exact trigger for this immune response remain unclear, several autoimmune hypotheses have been proposed. Early researchers suggested a role for antibodies against GluR3, a subunit of AMPA-type glutamate receptors but these findings have not been consistently replicated.[17][18] Recent research has identified auto antibodies against the anti-NDMA receptor subunit GluRepsilon2 (NR2A), these are not consistently present across cases and may represent a secondary epiphenomenon rather than a primary pathogenic mechanism.[19] There is limited evidence for auto antibodies targeting the nicotinic acetylcholine receptor.[18]

Emerging immunological studies have shown that patients display persistent peripheral expansion of cloncally restricted CD8+ T cells, which are theorized to cross the blood brain barrier and sustain cortical inflammation for years.[8] Suggesting an antigen-drive, chronic immune response that initiates in the periphery and targets CNS antigen. The epilepsy observed in Rasmussen's encephalitis is a potential amplifier of immune-mediated damage, through mechanisms involving excitotoxicity and impaired GABAergic inhibition.[20]

Rare associations with systemic autoimmune disorders, such as neurovisceral porphyria and acute intermittent porphyria, have been reported in isolated cases.[21]

## Diagnosis

Brain biopsy in Rasmussen's encephalitis showing lymphocytic infiltrates staining for CD8 on immunohistochemistry

Early multidisciplinary diagnostic approach is essential as delayed diagnosis may lead to irreversible neurological decline.[12]

Diagnosis of Rasmussen's encephalitis is made through combination of clinical evaluation, electrophysiological findings, and neuroimaging, with invasive procedures deem not necessary.[2][1]

Electroencephalography (EEG) is a crucial diagnostic tool, revealing focal epileptiform discharge and slowing of background activity in affected hemisphere. Over time, these abnormalities often display more lateralized and severe form of epilepsy.[22][4]

Magnetic resonance imaging (MRI) showcase the progressive hemispheric atrophy, often beginning in the frontal or insular regions, then expanding posteriorly. In early phases, brain scans reveal cortical swelling and T2/FLAIR hyperintensites consistent with inflammation. In later stages, this evolves into clear volume loss, ventricular enlargement, and gliosis.[1][13]

Brain biopsy is not always required. It can provide definitive histopathology confirmation, especially atypical presentations ow when alternative diagnoses (tumors or other forms of encephalitis) are being considered. When retrieved the tissue analysis can also help rule out infections, neoplatic, or demyelinating processes.[2][3][5]

## Treatment

Treatment is typically divided into two phases: management of active inflammation in acute stage and control long-term neurological symptoms in the residual stage.[12]

During the acute stage, the primary goal is to suppress the autoimmune response and slow neurological decline. The first treatment usually include high dose corticosteroids, either as intravenous methylprednisolone pulses or as oral maintenance therapy.[1] Intravenous immunoglobulin (IVIG) shown benefit in both pediatric and adult cases, often used monthly to modulate immune activity and reduce seizure frequency.[1][23] Other immunotherapies such as plasmapheresis, azathioprine, clyclophosphamide, mycophenolate mofetil, and tacrolimus have been used at varying success, though clinical trials are still in progress.[14][5] While these therapies can delay disease progression, they do not consistently prevent long term disability and responses varies between individuals.[12][5]

In chronic, or residual stage, the inflammatory activity subsides but neurological damage is often irreversible. Treatment shifts toward symptom management, especially seizure control. Standard anti-seizure medications are typically ineffective due to the focal drug resistant nature of the epilepsy.[4] For many patients, functional hemispherectomy (surgical disconnection or removal of the affected hemisphere) becomes the most effective option to stop seizures.[1][2] Variants such as anatomical hemispherectomy or hemispherotomy may be chosen based on age and severity of deficits.[13]

While hemispherectomy is associated with significant risks, such as permanent hemiplegia, hemianopia, and potential language loss if the dominant hemisphere is removed. It is often used as results in dramatic seizure reduction or remission for better quality of life. Early surgery in children, especially those under age 10, may offer better functional reorganization and recovery of language and cognitive skills by the contralateral hemisphere.[1][13]

Due to the severity of the procedure and its implications, some centers prioritizing early surgery and others favoring prolonged immunotherapy before considering invasive intervention.[12][14]

## History

It is named after Dr. Theodore Rasmussen (1910–2002), a pioneering neurosurgeon who succeeded Wilder Penfield as head of the Montreal Neurological Institute, and served as Neurosurgeon-in-Chief at the Royal Victoria Hospital.[2] In the 1950s, Rasmussen and colleagues described a series of children presenting intractable focal seizures, progressive hemiparesis, and unilateral cerebral atrophy. Initially referred to as "focal seizures due to chronic localized encephalitis".[7] His clinical observations and early histopathological analyses, often based on tissue obtained from hemispherectomy procedures, led to recognition of the disorders as distinct clinical and neuropathological entity.[13]

Although Rasmussen brought modern recognition, similar cases had been described decades earlier by Dr. A. Ya. Kozhevnikov, a Russian neurologist in Siberia during the 1880s. Kozhevnikov reported chronic focal motor seizures now recognized as EPC, a defining symptom of Rasmussen's encephalitis, in adult patients.[6] The disorder was referred to in some literature as Kozhevnikov epilepsy, highlighting its motor manifestations. It wasn't until the 1980s that researchers unified these clinical concepts and redefined the condition under the name Rasmussen's syndrome (or encephalitis), recognizing the autoimmune and progressive nature of the disease beyond motor seizures alone.[3][1]

## Society

The Hemispherectomy Foundation was formed in 2008 to assist families with children who have Rasmussen's encephalitis and other conditions that require hemispherectomy.[24]

## References

1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 Dalmau, Josep; Graus, Francesc (2022-01-27). Autoimmune Encephalitis and Related Disorders of the Nervous System. Cambridge University Press. doi:10.1017/9781108696722. ISBN 978-1-108-69672-2.
2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 Varadkar, Sophia; Bien, Christian G; Kruse, Carol A; Jensen, Frances E; Bauer, Jan; Pardo, Carlos A; Vincent, Angela; Mathern, Gary W et al. (February 2014). "Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances". The Lancet Neurology 13 (2): 195–205. doi:10.1016/s1474-4422(13)70260-6. ISSN 1474-4422.
3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 Bien, C. G. (2005-01-05). "Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: A European consensus statement" (in en). Brain 128 (3): 454–471. doi:10.1093/brain/awh415. ISSN 1460-2156. PMID 15689357. https://academic.oup.com/brain/article-lookup/doi/10.1093/brain/awh415.
4. ↑ 4.0 4.1 4.2 4.3 4.4 4.5 Fauser, Susanne; Elger, Christian E.; Woermann, Friedrich; Bien, Christian G. (2021-11-24). "Rasmussen encephalitis: Predisposing factors and their potential role in unilaterality". Epilepsia 63 (1): 108–119. doi:10.1111/epi.17131. ISSN 0013-9580.
5. ↑ 5.0 5.1 5.2 5.3 5.4 5.5 Kumar, Abhishek; Krishnani, Harshil; Pande, Arundhati; Jaiswal, Siddhant; Meshram, Revat J (2023-10-26). "Rasmussen's Encephalitis: A Literary Review". Cureus 15 (10). doi:10.7759/cureus.47698. ISSN 2168-8184. PMID 38022088.
6. ↑ 6.0 6.1 Vein, Alla A.; van Emde Boas, Walter (2011-01-04). "Kozhevnikov epilepsy: The disease and its eponym". Epilepsia 52 (2): 212–218. doi:10.1111/j.1528-1167.2010.02900.x. ISSN 0013-9580. PMID 21204824.
7. ↑ 7.0 7.1 Rasmussen, Theodore; Olszewski, Jerzy; Lloyd-Smith, Donald (June 1958). "Focal seizures due to chronic localized encephalitis" (in en). Neurology 8 (6): 435. doi:10.1212/WNL.8.6.435. ISSN 0028-3878. PMID 13566382. https://www.neurology.org/doi/10.1212/WNL.8.6.435.
8. ↑ 8.0 8.1 Schneider-Hohendorf, Tilman; Mohan, Hema; Bien, Christian G.; Breuer, Johanna; Becker, Albert; Görlich, Dennis; Kuhlmann, Tanja; Widman, Guido et al. (2016-04-04). "CD8+ T-cell pathogenicity in Rasmussen encephalitis elucidated by large-scale T-cell receptor sequencing" (in en). Nature Communications 7 (1). doi:10.1038/ncomms11153. ISSN 2041-1723. PMID 27040081. PMC 4822013. https://www.nature.com/articles/ncomms11153.
9. ↑ Bauer, Tobias; von Wrede, Randi D.; Pujar, Suresh; Rácz, Attila; Hoppe, Christian; Baumgartner, Tobias; Varadkar, Sophia; Held, Nina R. et al. (2024-08-14). "Rasmussen's encephalitis: structural, functional, and clinical correlates of contralesional epileptiform activity". Journal of Neurology 271 (10): 6680–6691. doi:10.1007/s00415-024-12607-7. ISSN 0340-5354. PMID 39138652.
10. ↑ 10.0 10.1 Owens, Geoffrey C.; Chang, Julia W.; Huynh, My N.; Chirwa, Thabiso; Vinters, Harry V.; Mathern, Gary W. (2016-02-23). "Evidence for Resident Memory T Cells in Rasmussen Encephalitis". Frontiers in Immunology 7. doi:10.3389/fimmu.2016.00064. ISSN 1664-3224. PMID 26941743.
11. ↑ Millichap, John J.; Goldstein, Joshua L. (2023-04-18). "Teaching Neuro Images: Long-term outcome of untreated Rasmussen syndrome". Neurology 100 (16_supplement_1). doi:10.1212/wnl.0000000000206924. ISSN 0028-3878.
12. ↑ 12.0 12.1 12.2 12.3 12.4 12.5 Stredny, Coral M.; Steriade, Claude; Papadopoulou, Maria T; Pujar, Suresh; Kaliakatsos, Marios; Tomko, Stuart; Wickström, Ronny; Cortina, Christopher et al. (November 2024). "Current practices in the diagnosis and treatment of Rasmussen syndrome: Results of an international survey". Seizure: European Journal of Epilepsy 122: 153–164. doi:10.1016/j.seizure.2024.09.001. ISSN 1059-1311.
13. ↑ 13.0 13.1 13.2 13.3 13.4 13.5 Pardo, Carlos A.; Vining, Eileen P. G.; Guo, Liping; Skolasky, Richard L.; Carson, Benjamin S.; Freeman, John M. (May 2004). "The Pathology of Rasmussen Syndrome: Stages of Cortical Involvement and Neuropathological Studies in 45 Hemispherectomies". Epilepsia 45 (5): 516–526. doi:10.1111/j.0013-9580.2004.33103.x. ISSN 0013-9580.
14. ↑ 14.0 14.1 14.2 Takahashi, Yukitoshi; Yamazaki, Etsuko; Mine, Jun; Kubota, Yuko; Imai, Katsumi; Mogami, Yuki; Baba, Koichi; Matsuda, Kazumi et al. (September 2013). "Immunomodulatory therapy versus surgery for Rasmussen syndrome in early childhood" (in en). Brain and Development 35 (8): 778–785. doi:10.1016/j.braindev.2013.01.010. PMID 23433490. https://linkinghub.elsevier.com/retrieve/pii/S0387760413000697.
15. ↑ Gulati, Parveen; Agarwal, Ankita; Garg, Kanwaljeet; Gulati, Aishwarya (2021). "Rasmussen Encephalitis with Ipsilateral Brain Stem and Contralateral Cerebellar Atrophy". Neurology India 69 (4): 1140. doi:10.4103/0028-3886.325356. ISSN 0028-3886.
16. ↑ Messacar, Kevin; Fischer, Marc; Dominguez, Samuel R.; Tyler, Kenneth L.; Abzug, Mark J. (March 2018). "Encephalitis in US Children". Infectious Disease Clinics of North America 32 (1): 145–162. doi:10.1016/j.idc.2017.10.007. ISSN 0891-5520. PMID 29224854.
17. ↑ Rogers, Scott W.; Andrews, P. Ian; Gahring, Lorise C.; Whisenand, Teri; Cauley, Keith; Crain, Barbara; Hughes, Thomas E.; Heinemann, Stephen F. et al. (1994-07-29). "Autoantibodies to Glutamate Receptor GluR3 in Rasmussen's Encephalitis" (in en). Science 265 (5172): 648–651. doi:10.1126/science.8036512. ISSN 0036-8075. Bibcode: 1994Sci...265..648R. https://www.science.org/doi/10.1126/science.8036512.
18. ↑ 18.0 18.1 Watson, R.; Jepson, J.E.C.; Bermudez, I.; Alexander, S.; Hart, Y.; McKnight, K.; Roubertie, A.; Fecto, F. et al. (2005-12-13). "α7-Acetylcholine receptor antibodies in two patients with Rasmussen encephalitis" (in en). Neurology 65 (11): 1802–1804. doi:10.1212/01.wnl.0000191566.86977.04. ISSN 0028-3878. PMID 16344526. https://www.neurology.org/doi/10.1212/01.wnl.0000191566.86977.04.
19. ↑ Takahashi, Yukitoshi; Mori, Hisashi; Mishina, Masayoshi; Watanabe, Masahiko; Kondo, Naomi; Shimomura, Jiro; Kubota, Yuko; Matsuda, Kazumi et al. (July 2005). "Autoantibodies and Cell-mediated Autoimmunity to NMDA-type GluRɛ2 in Patients with Rasmussen's Encephalitis and Chronic Progressive Epilepsia Partialis Continua" (in en). Epilepsia 46 (s5): 152–158. doi:10.1111/j.1528-1167.2005.01024.x. ISSN 0013-9580. PMID 15987271. https://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2005.01024.x.
20. ↑ Rassner, Michael P.; van Velthoven-Wurster, Vera; Ramantani, Georgia; Feuerstein, Thomas J. (March 2013). "Altered transporter-mediated neocortical GABA release in R asmussen encephalitis" (in en). Epilepsia 54 (3). doi:10.1111/epi.12093. ISSN 0013-9580. https://onlinelibrary.wiley.com/doi/10.1111/epi.12093.
21. ↑ Tziperman, Barak; Garty, Ben-Zion; Schoenfeld, Nili; Hoffer, Vered; Watemberg, Nathan; Lev, Dorit; Ganor, Yonathan; Levite, Mia et al. (January 2007). "Acute Intermittent Porphyria, Rasmussen Encephalitis, or Both?" (in en). Journal of Child Neurology 22 (1): 99–105. doi:10.1177/0883073807299962. ISSN 0883-0738. PMID 17608316. https://journals.sagepub.com/doi/10.1177/0883073807299962.
22. ↑ St. Louis, Erik; Frey, Lauren; Britton, Jeffrey; Hopp, Jennifer; Korb, Pearce; Koubeissi, Mohamad; Lievens, William; Pestana-Knight, Elia (2016). Electroencephalography (EEG): An Introductory Text and Atlas of Normal and Abnormal Findings in Adults, Children, and Infants. American Epilepsy Society. doi:10.5698/978-0-9979756-0-4. ISBN 978-0-9979756-0-4.
23. ↑ Hart, Y. M.; Cortez, M.; Andermann, F.; Hwang, P.; Fish, D. R.; Dulac, O.; Silver, K.; Fejerman, N. et al. (June 1994). "Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy): Effect of high-dose steroids or immunoglobulins in 19 patients" (in en). Neurology 44 (6): 1030. doi:10.1212/WNL.44.6.1030. ISSN 0028-3878. https://www.neurology.org/doi/10.1212/WNL.44.6.1030.
24. ↑ "The Community News". http://www.community-news.com/node/3302.

## External links

Classification|

* ICD-10: G04.8
* ICD-9-CM: 323.81
* DiseasesDB: 33757

|

* Rasmussen's Encephalitis at NINDS (Note: parts of this entry were copied from this Public Domain source.)

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Rasmussen syndrome. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Medicine:Rasmussen_syndrome&oldid=4017522"